Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Roche and Ionis report a 43.1% Phase 3 proteinuria reduction with sefaxersen. Two-year kidney function results remain the next major test.
Pharma & Biotech
Pharma & Biotech
Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy
Vertex's RAINIER trial shows 52% proteinuria reduction with povetacicept ahead of a November 30 FDA decision. Can it stand out in IgA nephropathy?
Pharma & Biotech
What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research?
GondolaBio and Children's Tumor Foundation are partnering on a preclinical NF1 programme, with patient expertise and programme equity at the centre of the deal.
Pharma & Biotech
Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab
Summit Therapeutics and Lunit will study AI-derived tumor biomarkers for ivonescimab, while clinical validation and patient-selection benefits remain unproven.
Pharma & Biotech
Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Travere's FILSPARI reduced four IgA nephropathy biomarkers in new PROTECT data, adding evidence on kidney protection without proving disease modification.
Pharma & Biotech
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
Genialis reports improved cancer response prediction using small patient cohorts and longitudinal AI analysis. Clinical validation remains the next hurdle.
Pharma & Biotech
AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.
Pharma & Biotech
Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
Galderma wins China approval for Relfydess after positive Phase 3 frown line results. Competition and its pending US review remain crucial.
Pharma & Biotech
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Merck and Moderna report 42% lower melanoma recurrence risk with intismeran plus Keytruda. Survival, safety and manufacturing remain key.
Pharma & Biotech
Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Drug Farm reports DF-003 reduced kidney fibrosis in preclinical research, revealing a potential ALPK1 treatment pathway. Human efficacy remains unproven.